A phase 1, randomized, double-blind, placebo-controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of VNA-318 in healthy male subjects
This is an early research study, often called a Phase 1 trial, and it's looking at a new medicine named VNA-318. The main goal is to understand if VNA-318 is safe and how well healthy men can handle it. Researchers will also be checking how the body processes the medicine and what effects it has. This study is for men aged 18 and over who are healthy. Because this is the very first time this medicine is being given to people, the study design involves comparing different doses of VNA-318 with a 'dummy' medicine (placebo), where neither the participant nor the study team knows who is getting what. This helps us get a clear picture of the medicine's effects.
At a glance
What is this study about?
Imagine your brain is like a super-computer, and sometimes as we get older or due to certain conditions, it might not work as quickly or clearly as it used to. This can affect things like memory, problem-solving, and attention, which doctors call 'cognitive impairment.' Researchers are always looking for new ways to help people whose brains aren't working as well as they could be.
This particular study is a very early step in checking a new medicine, called VNA-318, that might one day help with these thinking and memory problems. However, this first study isn't actually trying to treat people with memory problems. Instead, it's looking at healthy volunteers. The main reason for this is to make sure the medicine is safe and doesn't cause too many side effects when it's given to people for the first time.
Think of it like testing a new car engine for the first time in a lab before putting it into a car on the road. We need to understand how it works and if it's reliable. In this study, we'll be giving healthy men different amounts of VNA-318, or a dummy treatment, to see what happens. This is a crucial first step before the medicine can ever be tested in people who actually have memory and thinking difficulties.
Key takeaways
- This is an early study of a new medicine called VNA-318.
- It aims to check the safety and how the medicine behaves in healthy men aged 18 and over.
- Participants will receive either the new medicine or a dummy pill (placebo).
- It's a first step towards potentially finding new treatments for thinking and memory problems.
- There's no direct personal health benefit for participants in this study.
- You can stop taking part at any time.
Who may be eligible?
This study is looking for healthy men to take part. To be considered, you need to be at least 18 years old. There's no upper age limit mentioned, but you must be in good general health.
Being 'healthy' means you don't have any major ongoing medical conditions that could make taking the study medicine unsafe or affect the results. This includes things like serious heart problems, kidney disease, or other conditions that might require regular medication.
More detailed health checks will be done by the study team, including a physical exam and blood tests, to make sure this study is safe and right for you. If you're a man aged 18 or older and feel you're generally healthy, you might be able to take part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you a man?
- Are you 18 years old or older?
- Do you consider yourself generally healthy?
- Do you not have any major ongoing medical conditions or take many regular medicines?
What does participation involve?
If you decide to take part, you'll first have a screening visit to check if you're suitable. This will involve health checks, blood tests, and a discussion about the study. If you qualify, you will receive either the study medicine (VNA-318) or a placebo (a dummy medicine that looks the same but has no active ingredient). You won't know which one you're getting, and neither will the study staff – this is called 'double-blind'.
You'll likely need to stay at the study clinic for a period after receiving the medication so doctors can carefully monitor you for any effects or side effects. This might happen multiple times as different doses are given. You'll also have several follow-up visits or phone calls after you've left the clinic to check on your health and any long-term effects. The total duration of your involvement will depend on how many doses you receive and the follow-up schedule, but full details will be explained by the study team.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What does 'Phase 1' mean for a medical study?
Phase 1 means it's one of the very first times a new medicine is given to people. The main goal is to check its safety and how the body handles it, rather than treating a specific illness.
Why is this study only for men?
Often, early studies choose a single sex to simplify the initial safety assessment, as drug effects can sometimes differ between men and women. Future studies might include women.
What is a 'placebo'?
A placebo is a 'dummy' treatment that looks exactly like the real medicine but contains no active drug. It helps researchers compare the real medicine's effects against something that isn't active.
Will I know if I'm getting the real medicine or the placebo?
No, this is a 'double-blind' study, meaning neither you nor the study doctors will know whether you're getting VNA-318 or the placebo. This helps make the study results more accurate.
Will I get paid for taking part?
Sometimes, studies offer reimbursement for your time, travel, and inconvenience. This will be fully explained to you by the research team if you are eligible.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.